Introduction: There is an increasing interest in platelet-rich plasma (PRP) injection as a treatment for chronic plantar fasciopathy (PF). We wished to evaluate the evidence for the use of PRP in PF/fasciitis.
Introduction
Plantar fasciopathy (PF) is a frequent disorder involving the plantar fascia: it has a bimodal distribution and occurs in both athletes and sedentary subjects.
Usually syndromes that involve manifestation of the typical heel pain are called plantar fasciitis, but that term is not correct, because no histological evidence of inflammation is present in this condition; the terms 'fasciosis' or 'fasciopathy' are most appropriate terms to define heel pain associated with degeneration of the plantar fascia and atrophy of the abductor digiti minimi muscle. 1, 2 Even though the exact aetiology is unknown, collagen degeneration at the origin of the plantar fascia, caused by repetitive microtears, appears to be the basis of the pain. 3 To our knowledge, all authors have agreed that, in the first phases of the condition, the management should be non-operative. Several treatment options have been described with variable results, including rest, weight loss, deep massage, heel cups, night splint, anti-inflammatory drugs and stretching exercises. [4] [5] [6] [7] However, ∼10% of patients do not respond to conservative therapies, necessitating further aggressive procedures such as injection therapy, extracorporeal shock wave therapy and, in some cases, surgical release of the plantar fascia. [4] [5] [6] 8 CCS injections can be effective in improving symptoms, but are associated with various complications such as rupture of the plantar fascia, calcaneal osteomyelitis and fat pad atrophy. 9, 10 Platelet-rich plasma (PRP) is an autologous blood product in which the platelets have been concentrated. Several preclinical studies have shown PRP to be beneficial to tendon healing, possibly because of its anti-inflammatory property and the ability of the platelets to release several growth factors upon activation. 11 There is an increasing interest in PRP injections as a treatment for chronic PF, and recently several papers on this topic have been published. [12] [13] [14] [15] [16] [17] [18] [19] This review aims to provide a complete evaluation of all studies concerning PRP injection therapy for PF as well as a detailed assessment of the methodological quality of these studies.
Methods
This systematic review was performed following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement.
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Literature search A comprehensive, systematic literature search was performed in June 2014. The databases of MEDLINE (PubMed), EMBASE, CINAHL (Cumulative Index to Nursing and Allied Health Literature) and the Cochrane library were searched without time limits. The following key words were used in different combinations: 'plantar fasciitis', 'plantar fasciosis', 'plantar fasciopathy', 'heel pain', 'platelet rich plasma', 'platelet transfusion', 'prp' or 'injection'. We limited the search to articles in English, and only human studies were included. All titles and abstracts were assessed by two researchers (E.F. and M.P.), and all relevant articles were obtained. All bibliographies were also hand searched to identify further relevant literature.
All relevant articles were read independently in full text by two researchers to assess whether they met the inclusion criteria. If there was a difference in opinion on their suitability, a consensus was reached by consulting a third senior reviewer.
Study selection
All participants in the trials had to have a clinical diagnosis of PF/fasciitis.
Studies were included if their design could be classified into one of the three categories: randomized controlled trial, prospective comparative study and prospective cohort study. We imposed no exclusion relying on publication year. Articles were included if reporting clinical outcomes of at least a group of patients undergoing PRP injection, and the intervention had to be well described.
Data extraction
Two researchers independently recorded the study design, population, intervention, outcome measure and outcome using standardized data extraction forms. To assess the efficacy of the interventions, mean values of the continuous outcomes were extracted from the published articles.
Quality assessment
The Coleman methodology score (CMS), a 10-items validated system, 22 was used to evaluate each papers.
Two different authors (R.P. and M.P.) assessed the methodological quality of each study, first separately, and then discussing to reach an agreement when a difference >2 points was found. An investigation scoring 100 would represent the ideal design of a study, without bias or influence of casual factors.
Results

Literature search
Of the 164 articles initially identified by the search, 8 2, 13, 14, [16] [17] [18] [19] 23 met the inclusion criteria (Fig. 1) .
Study design, level of evidence
All studies included were prospective; 2, 13, 14, [16] [17] [18] [19] 23 of these, three 14, 17, 23 were level I controlled randomized trials.
Subjects' selection and inclusion criteria
Selection criteria of patients were reported with fairly detailed descriptions in all the papers. In all studies, patients needed to have a diagnosis of PF to be enrolled in the trials and receive injection therapies. Martinelli et al. 18 and Kim and Lee 17 required, in addition to the clinical diagnosis, a radiographic evidence of calcaneal spur and a plantar fascia thickness ≥4 mm at ultrasound, respectively. In all studies, a failure of other previous conservative treatments was mandatory to be included in the trials (Table 1 for full details).
Participants
Based on the available data, the 8 papers selected evaluate a total of 256 participants (264 plantar fascias treated), of whom 180 underwent PRP injections (188 plantar fascia). Ninety-three patients were male and 163 were female, with a ratio male/female of 0.63. The mean age of the patients involved in all the studies was 45.43 years (Table 1) .
Interventions
Each study used a different device to prepare PRP. Two studies were used a double centrifugation instead of a single cycle. The PRP volume injected ranged from 2.5 16 to 5 ml. 18, 19 Four out of eight studies 13, 17, 19, 23 reported the final concentration of platelets; it ranged from at least 2x 19 injected each foot three times. All studies advised a rest period ranging from 2 days to 4 weeks; five studies 2, 14, 16, 19 provided also a post-procedure rehabilitation programme, often involving stretching exercises. (Table 2) The duration of the follow-up ranged from 6 weeks 23 to 24 months.
Outcome measures
Different scores were used to evaluate the outcomes (Figs. 2 and Table 3 ). The most frequently used test was the VAS (Visual analogue scale) score. Roles and Maudsley scores were recorded in three of eight studies. The AOFAS (American Orthopaedic Foot and Ankle Society) score were used in two studies. Plantar fascia bands thickness was evaluated by ultrasound in one article.
Outcomes data
Effectiveness of PRP Ragab and Othman 19 in 2012 evaluated 25 participants treated with a single injection of PRP. At 12 months post-intervention, the average VAS pain decreased from 9.1 to 2.1. The patient's questionnaire showed no limitation of activity for 15 patients (60%), minimal limitation for 8 of them (32%), and moderate limitation for 2 (8%), with 22 of 25 patients completely satisfied of the therapy (88% of success rate). Ultrasonography thickness measurements of the plantar fascia revealed improvements for both medial and central bands.
In a prospective uncontrolled study, Martinelli et al. 18 obtained, after 12 months, a marked improvement in terms of VAS after the treatment with PRP, namely from 7.1 ± 1.1 to 1.9 ± 1.5. Eleven of 14 patients were classified excellent or good based on the Roles and Maudsley score. Kumar et al. 16 evaluated, through VAS, AOFAS and Roles and Maudsley scores, 44 patients (50 heels) prospectively enrolled. At all follow-up appointments planned (3rd and 6th month), a statistically significant improvement was recorded in all scores. The most recent trial to date to assess the efficacy and safety of PRP 13 showed a statistically significant improvement in terms of FAAM score (Foot and single-blinded study compared 10 patients undergoing two PRP injections with 11 patients treated with 2 injections of dextrose/lidocaine solution (DP). They lost one patient from the PRP group. At the 2-and 6-month follow-up appointments, they evaluated pain, disability and activity limitation of the 20 remaining patients, using the Foot Functional Index (FFI). The mean final FFI total score was improved for both the PRP group and the DP group, from 151.5 ± 37.9 at the baseline to 81.6 ± 55.3 for the PRP group and from 132.5 ± 31.1 to 97.7 ± 52.5 for the DP group. The improvement was greater for the PRP group (30.4 vs. 15.1%), but there was no statistically significant difference between the two groups at any follow-up (see Table 3 for FFI subscales details).
PRP vs. CCS therapy
In 2011 an Egyptian study 23 compared steroid injection (n = 15) (control group) with PRP injection (n = 15) (PRP group). After a follow-up of 6 weeks, a statistically significant difference was recorded for VAS and FHSQ (Foot Health Status Questionnaire) scores between the PRP and control groups (2.6 ± 2 vs. 6.5 ± 2.6, P = 0.001 and 25. (Table 4) .
Safety of PRP therapy
None of the articles analysed in this systematic review recorded any complication or adverse effect related to PRP administration.
Methodological quality
The modified CMS ranged from 61 to 81, 17 with a mean value of 74.23 and a standard deviation of 6.27 (Table 5 ). The Spearman correlation coefficient showed no significant correlation between Coleman data and the year of publication (P = −0.27).
Discussion
This systematic review evaluated the current evidence for application of PRP in PF, focusing on the effectiveness and safety of this therapeutic modality.
Plantar fasciopathy is the most common cause of heel pain, accounting for >1 million medical consultations per year only in the USA, with an incidence rate of ∼10%.
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A careful medical evaluation of clinical symptoms usually allows diagnosing the condition.
PF occurs especially in athletes and is supposed to be caused by continuous excessive overload. 25 Similarly to other overuse injuries, PF is often self-resolving. However, the continuous microtrauma caused by overuse initially results in microtears of the tissue substance, but then, if the noxious insult continues, it produces a macro injury, and the condition becomes chronic. 25, 26 A combination of intensive use (so-called repetitive microtrauma) and anomalous microvascular response results in reduced blood flow; reduced vascularization provides less oxygen and nutrients, slowing the healing processes and encouraging degenerative ones. Histological studies confirm this hypothesis, showing no acute inflammation, but rather a failure of the healing process associated with angiofibroblastic degeneration, collagen necrosis, chondroid metaplasia and matrix calcification. [27] [28] [29] In conclusion, in plantar fasciopathy, similarly to other tendinopathies, a failed healing response of the tendon occurs. 30 The rationale of the use of PRP is based on the growth factors stored in the alpha granules of platelets. Those factors, such as TGF-β (transforming growth factor beta), VEGF (vascular endothelial growth factor) and PDGF ( platelet-derived growth factor), stimulate tissue regeneration from mesenchymal cells, acting on both cell replication and differentiation. The tissue microenvironment determines phenotypic differentiation. Furthermore, platelets activated by thrombin release additional cytokines able to promote tendon cell proliferation.
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In this systematic review, we analysed all prospectively designed studies focusing on PRP injection therapy for the treatment of PF. We included eight publications, 2, 13, 14, [16] [17] [18] [19] 23 of which three studies 14, 17, 23 were randomized controlled clinical trials. We analysed the methodological quality of the papers included using the CMS, 22 PRP had a significantly greater efficacy than CCS, both after a short-term follow-up of 6 weeks and after a longer period (24 months). Also in the retrospective cohort study by Shetty et al.,
12 at 3 months PRP was superior in all the evaluated scores compared with CCS injection. Although other studies have shown that injection of CCS are effective in treating the PF, [35] [36] [37] the effect seems to be limited and short lived; furthermore, the use of CCSs is not a pathology-based therapy and has been associated with the risks of fat pad atrophy and rupture of the plantar fascia. [6] [7] [8] Surgery remains the last treatment option when all previous therapy fail, but carries the risk of nerve injury, infection, plantar fascia rupture and does not always ensure a symptoms improvement. 38 Although the current evidence suggests that PRP may be of benefit as an injection therapy to treat plantar fasciopathy, a greater number of studies are needed to draw better conclusions on the use of PRP in PF.
To date, indeed, the total amount of patients treated with this therapy is still too limited to properly assess both effectiveness and safety.
Most of the articles included in this review were published in the last 2 years, showing the growing interest on the topic. Some level I studies are currently under way, such as the multicentre, randomized controlled study by Peerbooms et al. 39 Future studies should characterize the details of the intervention and standardize the outcome scores to help to find the best procedure and optimize treatment.
Furthermore, only one of the studies in our review reported an imaging evaluation of the plantar fascia: this is not enough to provide useful information; future studies should include an ultrasound evaluation before and after injection, given the role that this technique can play in assessing healing. 40, 41 This systematic review has some limitations. First, only articles published in English were included.
Moreover, no other kind of autologous blood injection, other than PRP, was considered. Our aim was to focus only on PRP products in which platelet concentrations were increased compared with standard autologous blood.
Most of the studies analysed do not have control groups and provide only results of patients undergoing PRP injection. Moreover, not even one of the controlled studies has a real placebo control group: randomized clinical trials comparing PRP with placebo are necessary, given the nature of PF, which is often self-limiting.
Conclusion
PRP injection therapy may be of benefit over purely conservative treatment and other injection therapy modalities to treat plantar fasciopathy. The current evidence is promising but limited, and therefore further high-quality research must be undertaken to both compare PRP versus placebo and better characterize the optimal preparation of PRP, the appropriate recipient, and the timing of the intervention to maximize any benefit it may have. To complement the clinical parameters that may be used to designate successful treatment, addressing the current lack of imaging documentation of the response to PRP therapy is also recommended.
